Search results
Results from the WOW.Com Content Network
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
Breakthrough T1D was founded in 1970 by a group of parents of children living with type 1 diabetes. [9] The founding members formed the organization with the intent to find a cure for type 1 diabetes and its complications by supporting research.
The mainstay of type 1 diabetes treatment is the regular injection of insulin to manage hyperglycemia. [48] Injections of insulin via subcutaneous injection using either a syringe or an insulin pump are necessary multiple times per day, adjusting dosages to account for food intake, blood glucose levels, and physical activity. [48]
The International Society for Pediatric and Adolescent Diabetes (ISPAD) is a professional organization that brings together doctors, nurses, dieticians, psychologists, scientists and other professionals to improve the treatment of children and families afflicted by diabetes throughout the world.
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
The Juvenile Diabetes Cure Alliance (JDCA) is a registered 501(c)(3) non-profit organization dedicated to developing a Practical Cure for type 1 diabetes.The organization advocates for increasing type 1 diabetes cure research and publishes reports on a variety of related topics, including research progress, fundraising utilization, and donor priorities.
This evidence convinced most physicians who specialize in diabetes care that an important goal of treatment is to make the biochemical profile of the diabetic patient (blood lipids, HbA1c, etc.) as close to the values of non-diabetic people as possible. This is especially true for young patients with many decades of life ahead.
MODY accounts for at least 1-5% of all diagnoses of diabetes mellitus, though 50-90% of cases are estimated to be misdiagnosed as type 1, or type 2 diabetes. [4] Estimated prevalence rates indicate 1 per 10,000 in adults, and 1 per 23,000 in children.